Breaking News

Saturday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
GSK says rejected 3 Unilever bids that 'undervalued' Consumer Healthcare unit » 16:37
01/15/22
01/15
16:37
01/15/22
16:37
GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

, UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

A press release was…

A press release was issued today by GlaxoSmithKline (GSK) to the London Stock Exchange, entitled "Update - GSK Consumer Healthcare," that states in part: "GlaxoSmithKline (GSK) plc today confirms that it has received three unsolicited, conditional and non-binding proposals from Unilever plc to acquire the GSK Consumer Healthcare business. The latest proposal received on 20th December 2021 was for a total acquisition value of GBP 50 billion comprising GBP 41.7 billion in cash and GBP 8.3 billion in Unilever shares. The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%. GSK rejected all three proposals made on the basis that they fundamentally undervalued the Consumer Healthcare business and its future prospects. The Board of GSK is strongly focused on maximising value for GSK shareholders and has carefully evaluated each Unilever proposal. In doing so, the Board and its advisers assessed the proposals relative to the financial planning assessments completed to support the proposed demerger of the business in mid-2022, including the sales growth outlook set out below... The business has an exceptional portfolio of world-class, category-leading brands; global scale with footprint and distribution capability to serve more than 100 markets; strong brand building, innovation and digital capabilities; and offers a unique proposition that combines trusted science with human understanding... The business is well-positioned to sustainably grow ahead of its categories in the years to come. The fundamentals for the GBP 150 billion consumer healthcare sector are strong, reflecting an increased focus on health and wellness, significant demand from an ageing population and emerging middle class, and sizeable unmet consumer needs. Over the period 2019-2021 the Consumer Healthcare business delivered a 4% organic sales growth CAGR2 outpacing its categories and despite the adverse impact of the COVID pandemic. Superior sales growth for the business is expected to result from a strategy that puts the consumer at the heart of the business to better address every-day health and wellness needs, in particular by increasing household penetration of its leading brands and capitalising on new and emerging growth opportunities arising from innovation and the use of new technologies and digital platforms, all underpinned by continued strong execution and financial discipline. Over the medium term, superior sales growth is expected to be primarily driven by continued momentum of key brands in Oral Care, VMS, and Pain Relief; accelerating innovation in the US and China; and further growth in emerging markets. Reflecting these trends, and the investments made and planned for the business, the Board of GSK is confident that the Consumer Healthcare business can sustainably deliver annual organic sales growth in the range of 4-6% CER over the medium term. The combination of superior organic sales growth, operating margin expansion and consistent high cash generation will, we believe, offer both existing and prospective shareholders a highly attractive financial profile that facilitates continued investment in growth, the delivery of attractive returns and the opportunity of continued participation in long-term value creation. The Board of GSK unanimously concluded that the proposals were not in the best interests of GSK shareholders as they fundamentally undervalued the Consumer Healthcare business and its future prospects. The Board of GSK therefore remains focused on executing its proposed demerger of the Consumer Healthcare business, to create a new independent global category-leading consumer company which, subject to approval from shareholders, is on track to be achieved in mid-2022. GSK intends to share further details of the strategy, brands, capabilities and operations, including detailed financial information and future growth ambitions for the new Consumer Healthcare business at a virtual Capital Markets Day for investors and analysts on Monday 28th February 2022."

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

Hot Stocks
Unilever confirms approach made to GSK, Pfizer about GSK Consumer Healthcare » 07:42
01/15/22
01/15
07:42
01/15/22
07:42
UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

, GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

Unilever (UN, UL) has…

Unilever (UN, UL) has issued the following statement in response to press reporting: "Unilever notes recent reporting regarding its interest in GSK Consumer Healthcare and confirms that it has approached GSK and Pfizer about a potential acquisition of the business. GSK Consumer Healthcare is a leader in the attractive consumer health space and would be a strong strategic fit as Unilever continues to re-shape its portfolio. There can be no certainty that any agreement will be reached."

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

Periodicals
GSK rejected unsolicited GBP 50B bid from Unilever for consumer unit, Times says » 07:40
01/15/22
01/15
07:40
01/15/22
07:40
UN

Unilever

$60.50 /

+ (+0.00%)

, UL

Unilever

$54.30 /

+0.645 (+1.20%)

, GSK

GlaxoSmithKline

$45.48 /

+0.44 (+0.98%)

, PFE

Pfizer

$54.94 /

-0.59 (-1.06%)

Unilever (UN, UL) made an…

Unilever (UN, UL) made an unsolicited bid for GlaxoSmithKline's (GSK) consumer goods business worth roughly GBP 50B, which was rejected on the basis that it was too cheap, The Sunday Times' Oliver Shah and Sabah Meddings reported. Drug making giant Pfizer (PFE), which owns a minority stake in the division, was involved in the decision to decline the offer, the report noted. Reference Link

ShowHide Related Items >><<
UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

01/10/22 Citi
Unilever resumed with a Buy at Citi
11/01/21 Bernstein
Unilever upgraded to Market Perform from Underperform at Bernstein
09/16/21 Deutsche Bank
Unilever downgraded to Hold from Buy at Deutsche Bank
09/02/21 JPMorgan
Unilever downgraded to Underweight from Neutral at JPMorgan
UL Unilever
$54.30 /

+0.645 (+1.20%)

09/02/21
Fly Intel: Top five analyst downgrades
GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

01/04/22 JPMorgan
GlaxoSmithKline price target raised to 1,710 GBp from 1,580 GBp at JPMorgan
01/04/22 JPMorgan
JPMorgan places 'positive Catalyst watch' on GSK, ups target
12/21/21 H.C. Wainwright
Vir Biotechnology price target raised to $300 from $200 at H.C. Wainwright
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

UN Unilever
$60.50 /

+ (+0.00%)

UL Unilever
$54.30 /

+0.645 (+1.20%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

PFE Pfizer
$54.94 /

-0.59 (-1.06%)

GSK GlaxoSmithKline
$45.48 /

+0.44 (+0.98%)

Friday
Hot Stocks
J&J announces settlement pact with New Mexico resolving opioid claims » 16:11
01/14/22
01/14
16:11
01/14/22
16:11
JNJ

Johnson & Johnson

$167.94 /

-0.84 (-0.50%)

Johnson & Johnson and…

Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies announced a settlement agreement with the State of New Mexico and its participating subdivisions resolving their opioid-related claims against the company. With this agreement, the company is removed from pending litigation by the State and its subdivisions. The $44M settlement with New Mexico is consistent with the terms of the previously announced nationwide opioid settlement agreement. The dollar amount to be received by the State is the pro-rated share it would have received under this agreement, which will be deducted from the all-in settlement amount. This settlement is not an admission of any liability or wrongdoing and the company will continue to defend against any litigation that the final agreement does not resolve. The company's actions relating to the marketing and promotion of important prescription opioid medications were appropriate and responsible. DURAGESIC, NUCYNTA and NUCYNTA ER accounted for less than one percent of total opioid prescriptions in New Mexico and the U.S. since launch. The company no longer sells prescription opioid medications in the United States as part of our ongoing efforts to focus on transformational innovation and serving unmet patient needs.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$167.94 /

-0.84 (-0.50%)

JNJ Johnson & Johnson
$167.94 /

-0.84 (-0.50%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
JNJ Johnson & Johnson
$167.94 /

-0.84 (-0.50%)

JNJ Johnson & Johnson
$167.94 /

-0.84 (-0.50%)

JNJ Johnson & Johnson
$167.94 /

-0.84 (-0.50%)

JNJ Johnson & Johnson
$167.94 /

-0.84 (-0.50%)

Hot Stocks
FDA approves Pfizer's Cibinqo for moderate-to-severe atopic dermatitis » 15:33
01/14/22
01/14
15:33
01/14/22
15:33
PFE

Pfizer

$54.98 /

-0.55 (-0.99%)

Pfizer announced that the…

Pfizer announced that the United States Food and Drug Administration approved Cibinqo, an oral, once-daily, Janus kinase 1, or JAK1, inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Cibinqo is approved at the recommended doses of 100 mg and 200 mg, with the 200 mg dose being recommended for patients who are not responding to the 100 mg dose. Additionally, a 50 mg dose was approved to treat moderate-to-severe AD specifically in patients with moderate renal impairment, certain patients receiving treatment with inhibitors of cytochrome P450 2C19, or patients who are known or suspected to be poor metabolizers of CYP2C19. For patients with moderate renal impairment who are not responding to 50 mg once daily, 100 mg once daily may also be prescribed. Cibinqo will be made available in the coming weeks, Pfizer said.

ShowHide Related Items >><<
PFE Pfizer
$54.98 /

-0.55 (-0.99%)

PFE Pfizer
$54.98 /

-0.55 (-0.99%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$54.98 /

-0.55 (-0.99%)

PFE Pfizer
$54.98 /

-0.55 (-0.99%)

PFE Pfizer
$54.98 /

-0.55 (-0.99%)

PFE Pfizer
$54.98 /

-0.55 (-0.99%)

Recommendations
Pfizer price target raised to $76 from $60 at BMO Capital » 06:53
01/14/22
01/14
06:53
01/14/22
06:53
PFE

Pfizer

$55.53 /

-1.11 (-1.96%)

BMO Capital analyst Evan…

BMO Capital analyst Evan Seigerman raised the firm's price target on Pfizer to $76 from $60 and keeps an Outperform rating on the shares while reiterating the stock as his Top Pick for 2022. Pfizer could be the first pharma company to break $100B revenues boosted by Paxlovid sales this year, the analyst tells investors in a research note. Seigerman adds that he estimates Paxlovid generating $30B in sales this year vs. consensus of $20B, stating that Pfizer should have the ability to use this cash flow to navigate the loss-of-exclusivity concerns.

ShowHide Related Items >><<
PFE Pfizer
$55.53 /

-1.11 (-1.96%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$55.53 /

-1.11 (-1.96%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

Thursday
On The Fly
Wall Street in Fives - Must Read Lists for Thursday » 16:25
01/13/22
01/13
16:25
01/13/22
16:25
DAL

Delta Air Lines

$41.50 /

+0.92 (+2.27%)

, KBH

KB Home

$49.39 /

+7 (+16.51%)

, TSM

TSMC

$139.19 /

+6.905 (+5.22%)

, NAVI

Navient

$21.97 /

+0.07 (+0.32%)

, PFE

Pfizer

$55.53 /

-1.11 (-1.96%)

, BNTX

BioNTech

$203.07 /

-18.11 (-8.19%)

, JNJ

Johnson & Johnson

$168.78 /

-1.03 (-0.61%)

, MRNA

Moderna

$210.14 /

-12.71 (-5.70%)

, SNAP

Snap

$38.36 /

-4.385 (-10.26%)

, BMBL

Bumble

$32.50 /

-0.16 (-0.49%)

, HD

Home Depot

$386.86 /

-2.55 (-0.65%)

, BIIB

Biogen

$236.70 /

+11.38 (+5.05%)

, D

Dominion

$79.74 /

+0.435 (+0.55%)

, TSLA

Tesla

$1,031.72 /

-73.99 (-6.69%)

, GS

Goldman Sachs

$390.94 /

+0.59 (+0.15%)

, BX

Blackstone

$118.93 /

-3.36 (-2.75%)

, BYND

Beyond Meat

$70.86 /

+3.25 (+4.81%)

, NKLA

Nikola

$10.20 /

-0.235 (-2.25%)

, GRUB

Just Eat Takeaway

$10.92 /

+0.73 (+7.17%)

, DNLI

Denali Therapeutics

$33.86 /

-4.67 (-12.12%)

, SPCE

Virgin Galactic

$10.02 /

-2.345 (-18.96%)

, GRWG

GrowGeneration

$9.89 /

-1.185 (-10.70%)

, AXDX

Accelerate Diagnostics

$4.06 /

-0.2 (-4.69%)

, BGFV

Big 5 Sporting

$19.88 /

+0.29 (+1.48%)

, QTRX

Quanterix

$33.03 /

-0.08 (-0.24%)

, CVET

Covetrus

$16.49 /

-1.61 (-8.90%)

, ETWO

E2open

$8.53 /

-1.175 (-12.11%)

, BHVN

Biohaven Pharmaceutical

$122.58 /

-1.2 (-0.97%)

, AUPH

Aurinia Pharmaceuticals

$18.70 /

+0.27 (+1.47%)

, AMLX

Amylyx

$21.38 /

+0.9 (+4.39%)

Get caught up quickly on…

ShowHide Related Items >><<
TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

QTRX Quanterix
$33.03 /

-0.08 (-0.24%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

NAVI Navient
$21.97 /

+0.07 (+0.32%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

GRUB Just Eat Takeaway
$10.92 /

+0.73 (+7.17%)

ETWO E2open
$8.53 /

-1.175 (-12.11%)

DNLI Denali Therapeutics
$33.86 /

-4.67 (-12.12%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

CVET Covetrus
$16.49 /

-1.61 (-8.90%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BMBL Bumble
$32.50 /

-0.16 (-0.49%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

BHVN Biohaven Pharmaceutical
$122.58 /

-1.2 (-0.97%)

BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

AXDX Accelerate Diagnostics
$4.06 /

-0.2 (-4.69%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

01/14/22 Raymond James
Delta Air Lines price target lowered to $53 from $55 at Raymond James
01/14/22 Barclays
Delta Air Lines price target lowered to $45 from $50 at Barclays
01/13/22 Goldman Sachs
Delta Air Lines price target raised to $40 from $39 at Goldman Sachs
01/13/22 Susquehanna
Delta Air Lines upgraded to Positive with $50 price target at Susquehanna
KBH KB Home
$49.39 /

+7 (+16.51%)

01/14/22 Seaport Global
KB Home downgraded to Neutral from Buy at Seaport Global
01/14/22 Raymond James
KB Home price target raised to $63 from $55 at Raymond James
01/13/22 Wedbush
KB Home price target raised to $73 from $60 at Wedbush
01/13/22 RBC Capital
KB Home price target raised to $55 from $46 at RBC Capital
TSM TSMC
$139.19 /

+6.905 (+5.22%)

01/12/22 DZ Bank
TSMC initiated with a Buy at DZ Bank
01/11/22 Cowen
TSMC price target raised to $125 from $120 at Cowen
01/11/22 New Street
New Street sees now as 'ideal timing to invest' in TSMC
11/01/21 Northland
Intel upgraded to Market Perform on new CEO's plan at Northland
NAVI Navient
$21.97 /

+0.07 (+0.32%)

01/13/22 Stephens
Stephens raises EPS estimates for Navient after state AG resolution
01/10/22 Barclays
Navient price target lowered to $25 from $26 at Barclays
01/03/22 Stephens
Navient downgraded to Equal Weight at Stephens on valuation
01/03/22 Stephens
Navient downgraded to Equal Weight from Overweight at Stephens
PFE Pfizer
$55.53 /

-1.11 (-1.96%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

12/22/21 Kempen
BioNTech upgraded to Buy from Neutral at Kempen
12/21/21 H.C. Wainwright
BioNTech price target raised to $366 from $360 at H.C. Wainwright
12/16/21 Morgan Stanley
BioNTech initiated with an Equal Weight at Morgan Stanley
12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
MRNA Moderna
$210.14 /

-12.71 (-5.70%)

01/06/22 Argus
Moderna price target lowered to $350 from $420 at Argus
01/05/22 Piper Sandler
Piper keeps $348 target on Moderna after Epstein-Barr vaccine trial starts
12/20/21 Piper Sandler
Piper keeps Overweight rating, $348 price target on Moderna after omicron data
12/16/21 Piper Sandler
Arcturus data shows 'legit player' in COVID vaccines, says Piper Sandler
SNAP Snap
$38.36 /

-4.385 (-10.26%)

01/13/22 Cowen
Snap downgraded to Market Perform from Outperform at Cowen
01/12/22 Craig-Hallum
Craig-Hallum bullish on BuzzFeed, initiates with a Buy
01/11/22 JPMorgan
Amazon 'strong favorite' to be best performing FANG stock, JPMorgan says
12/21/21 Loop Capital
Snap price target lowered to $68 from $79 at Loop Capital
BMBL Bumble
$32.50 /

-0.16 (-0.49%)

01/12/22 Goldman Sachs
Bumble upgraded to Buy from Neutral at Goldman Sachs
01/12/22 Piper Sandler
Bumble initiated with a Neutral at Piper Sandler
12/28/21 Evercore ISI
Evercore ISI's Mark Mahaney announces top internet picks for 2022
HD Home Depot
$386.86 /

-2.55 (-0.65%)

01/12/22 Truist
Home Depot upgraded to Buy at Truist, sees market share gain potential
01/12/22 Truist
Home Depot assumed with a Buy at Truist
01/06/22 Baird
Masco may ultimately be helped by pro expansion, says Baird
01/05/22 Wells Fargo
Home Depot price target raised to $460 from $420 at Wells Fargo
BIIB Biogen
$236.70 /

+11.38 (+5.05%)

01/14/22 Jefferies
Biogen remains 'open to all options on the table,' says Jefferies
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
D Dominion
$79.74 /

+0.435 (+0.55%)

01/12/22 Goldman Sachs
Dominion downgraded to Sell from Neutral at Goldman Sachs
01/05/22 UBS
Dominion upgraded to Buy from Neutral at UBS
01/05/22 UBS
Dominion upgraded to Buy from Neutral at UBS
10/19/21 JPMorgan
Dominion settlement 'clearing event' for shares, says JPMorgan
TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

01/12/22 New Street
New Street sees 50% upside in Tesla this year amid 'perfect storm'
01/11/22 Redburn
Redburn starts Lucid Group at Neutral on risks of competing against Tesla
01/10/22 Morgan Stanley
Tesla price target raised to $1,300 from $1,200 at Morgan Stanley
01/10/22 Goldman Sachs
Goldman ups Tesla price target, says best positioned in EVs
GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

01/06/22 BofA
Goldman Sachs downgraded to Neutral from Buy at BofA
01/03/22 Barclays
Goldman Sachs price target raised to $556 from $483 at Barclays
12/06/21 Morgan Stanley
Goldman Sachs upgraded to Equal Weight at Morgan Stanley
BX Blackstone
$118.93 /

-3.36 (-2.75%)

01/13/22 Deutsche Bank
Blackstone price target lowered to $176 from $190 at Deutsche Bank
12/17/21 Deutsche Bank
Blackstone price target raised to $190 from $152 at Deutsche Bank
12/16/21 BofA
Blackstone initiated with a Buy at BofA
12/16/21 BofA
Blackstone initiated with a Buy at BofA
BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

01/05/22 BofA
Beyond Meat price target lowered to $55 from $70 at BofA
01/05/22 Piper Sandler
Piper still 'bearish' on Beyond Meat despite pending positive headline
12/14/21 BTIG
McDonald's price target raised to $295 from $255 at BTIG
12/13/21 Piper Sandler
Beyond Meat upgraded to Neutral at Piper on pending McDonald's McPlant launch
NKLA Nikola
$10.20 /

-0.235 (-2.25%)

11/08/21 Wedbush
Nikola price target raised to $15 from $10 at Wedbush
11/05/21 BTIG
Nikola downgraded to Neutral from Buy at BTIG
09/09/21 JPMorgan
Nikola price target lowered to $12 from $21 at JPMorgan
08/11/21
Fly Intel: Top five analyst initiations
GRUB Just Eat Takeaway
$10.92 /

+0.73 (+7.17%)

01/14/22 Exane BNP Paribas
Just Eat Takeaway upgraded to Neutral from Underperform at Exane BNP Paribas
01/13/22 JPMorgan
Just Eat Takeaway price target lowered to 6,285 GBp from 6,527 GBp at JPMorgan
01/13/22 Credit Suisse
Just Eat Takeaway price target lowered to 7,400 GBp at Credit Suisse
01/11/22 Morgan Stanley
Just Eat price target lowered to 7,300 GBp from 9,900 GBp at Morgan Stanley
DNLI Denali Therapeutics
$33.86 /

-4.67 (-12.12%)

12/09/21 Raymond James
Denali Therapeutics assumed with a Market Perform at Raymond James
11/05/21 Evercore ISI
Denali Therapeutics price target raised to $111 from $70 at Evercore ISI
09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
09/01/21 SMBC Nikko
Denali Therapeutics initiated with an Outperform at SMBC Nikko
SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

01/14/22 Canaccord
Virgin Galactic price target lowered to $36 from $44 at Canaccord
01/13/22 Canaccord
Canaccord cuts Virgin Galactic target on offering but stays confident
10/19/21 Morgan Stanley
Virgin Galactic price target lowered to $17 from $25 at Morgan Stanley
10/18/21 UBS
Virgin Galactic downgraded to Sell from Neutral at UBS
GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

01/14/22 Craig-Hallum
GrowGeneration downgraded to Hold from Buy at Craig-Hallum
01/14/22 Stifel
GrowGeneration price target lowered to $10 from $24 at Stifel
01/14/22 Craig-Hallum
GrowGeneration downgraded to Hold from Buy at Craig-Hallum
01/13/22 Alliance Global Partners
GrowGeneration price target lowered to $20 from $35 at Alliance Global Partners
AXDX Accelerate Diagnostics
$4.06 /

-0.2 (-4.69%)

01/14/22 Craig-Hallum
Accelerate Diagnostics price target lowered to $9 from $12 at Craig-Hallum
07/07/21 Piper Sandler
Accelerate Diagnostics launches PhenoAST in the U.S., says Piper Sandler
05/10/21 Piper Sandler
Accelerate Diagnostics price target lowered to $9 from $12 at Piper Sandler
BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

08/04/21 Lake Street
Big 5 Sporting price target raised to $31 from $26 at Lake Street
05/05/21 Lake Street
Big 5 Sporting price target raised to $26 from $19 at Lake Street
03/03/21 Lake Street
Big 5 Sporting price target raised to $19 from $16 at Lake Street
QTRX Quanterix
$33.03 /

-0.08 (-0.24%)

10/14/21 Cowen
Quanterix coverage transferred at Cowen
06/04/21
Fly Intel: Top five analyst initiations
06/04/21 Goldman Sachs
Quanterix initiated with a Sell at Goldman Sachs
05/06/21 SVB Leerink
Quanterix price target lowered to $70 from $85 at SVB Leerink
CVET Covetrus
$16.49 /

-1.61 (-8.90%)

01/12/22 Goldman Sachs
Covetrus' 2022 Rx revenue outlook may be disappointing, says Goldman Sachs
11/18/21 Morgan Stanley
Covetrus initiated with an Equal Weight at Morgan Stanley
08/04/21 Credit Suisse
Covetrus assumed with a Neutral at Credit Suisse
07/12/21 Guggenheim
Covetrus upgraded to Buy from Neutral at Guggenheim
ETWO E2open
$8.53 /

-1.175 (-12.11%)

10/11/21 Loop Capital
E2open assumed with a Buy at Loop Capital
10/11/21 Loop Capital
E2open assumed with a Buy at Loop Capital
09/30/21 BofA
E2open initiated with a Neutral at BofA
04/21/21 Loop Capital
E2open initiated with a Buy at Loop Capital
BHVN Biohaven Pharmaceutical
$122.58 /

-1.2 (-0.97%)

01/03/22 Canaccord
Biohaven Pharmaceutical price target raised to $160 from $150 at Canaccord
12/06/21 Piper Sandler
Biohaven's zavegepant offers 'unmodeled upside,' says Piper Sandler
11/18/21 Mizuho
Biohaven Pharmaceutical price target raised to $144 from $135 at Mizuho
11/10/21 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $177 from $165 at Cantor Fitzgerald
AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

12/10/21 Oppenheimer
Aurinia Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
11/04/21 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $40 from $35 at H.C. Wainwright
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform on valuation at Oppenheimer
10/28/21 Oppenheimer
Aurinia Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
AMLX Amylyx
$21.38 /

+0.9 (+4.39%)

TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

QTRX Quanterix
$33.03 /

-0.08 (-0.24%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

NAVI Navient
$21.97 /

+0.07 (+0.32%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

ETWO E2open
$8.53 /

-1.175 (-12.11%)

DNLI Denali Therapeutics
$33.86 /

-4.67 (-12.12%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

CVET Covetrus
$16.49 /

-1.61 (-8.90%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BMBL Bumble
$32.50 /

-0.16 (-0.49%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

BHVN Biohaven Pharmaceutical
$122.58 /

-1.2 (-0.97%)

BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

AXDX Accelerate Diagnostics
$4.06 /

-0.2 (-4.69%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

  • 07
    Jan
  • 08
    Dec
  • 10
    Sep
  • 16
    Mar
  • 04
    Feb
  • 11
    Feb
TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRUB Just Eat Takeaway
$10.92 /

+0.73 (+7.17%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

QTRX Quanterix
$33.03 /

-0.08 (-0.24%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

NAVI Navient
$21.97 /

+0.07 (+0.32%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

GRUB Just Eat Takeaway
$10.92 /

+0.73 (+7.17%)

ETWO E2open
$8.53 /

-1.175 (-12.11%)

DNLI Denali Therapeutics
$33.86 /

-4.67 (-12.12%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BMBL Bumble
$32.50 /

-0.16 (-0.49%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

BHVN Biohaven Pharmaceutical
$122.58 /

-1.2 (-0.97%)

BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

AMLX Amylyx
$21.38 /

+0.9 (+4.39%)

TSM TSMC
$139.19 /

+6.905 (+5.22%)

TSLA Tesla
$1,031.72 /

-73.99 (-6.69%)

SPCE Virgin Galactic
$10.02 /

-2.345 (-18.96%)

SNAP Snap
$38.36 /

-4.385 (-10.26%)

PFE Pfizer
$55.53 /

-1.11 (-1.96%)

NKLA Nikola
$10.20 /

-0.235 (-2.25%)

NAVI Navient
$21.97 /

+0.07 (+0.32%)

MRNA Moderna
$210.14 /

-12.71 (-5.70%)

KBH KB Home
$49.39 /

+7 (+16.51%)

JNJ Johnson & Johnson
$168.78 /

-1.03 (-0.61%)

HD Home Depot
$386.86 /

-2.55 (-0.65%)

GS Goldman Sachs
$390.94 /

+0.59 (+0.15%)

GRWG GrowGeneration
$9.89 /

-1.185 (-10.70%)

ETWO E2open
$8.53 /

-1.175 (-12.11%)

DAL Delta Air Lines
$41.50 /

+0.92 (+2.27%)

D Dominion
$79.74 /

+0.435 (+0.55%)

BYND Beyond Meat
$70.86 /

+3.25 (+4.81%)

BX Blackstone
$118.93 /

-3.36 (-2.75%)

BNTX BioNTech
$203.07 /

-18.11 (-8.19%)

BMBL Bumble
$32.50 /

-0.16 (-0.49%)

BIIB Biogen
$236.70 /

+11.38 (+5.05%)

BGFV Big 5 Sporting
$19.88 /

+0.29 (+1.48%)

AUPH Aurinia Pharmaceuticals
$18.70 /

+0.27 (+1.47%)

Hot Stocks
Supreme Court allows healthcare worker vaccination rule to stand » 14:50
01/13/22
01/13
14:50
01/13/22
14:50
PFE

Pfizer

$55.66 /

-0.98 (-1.73%)

, BNTX

BioNTech

$206.90 /

-14.28 (-6.46%)

, MRNA

Moderna

$211.34 /

-11.51 (-5.16%)

, JNJ

Johnson & Johnson

$169.17 /

-0.64 (-0.38%)

The Supreme Court has…

The Supreme Court has ruled that vaccine requirements can stand for medical facilities that take Medicare or Medicaid payments, arguing that the Secretary of Health and Human Services has it within his power to mandate that, in order to receive Medicare and Medicaid funding, participating facilities must ensure that their staff-unless exempt for medical or religious reasons-are vaccinated against COVID-19. In the ruling, the high court states: "First, we agree with the Government that the Secretary's rule falls within the authorities that Congress has conferred upon him... Moreover, the Secretary routinely imposes conditions of participation that relate to the qualifications and duties of healthcare workers themselves... We accordingly conclude that the Secretary did not exceed his statutory authority in requiring that, in order to remain eligible for Medicare and Medicaid dollars, the facilities covered by the interim rule must ensure that their employees be vaccinated against COVID-19." Makers of COVID-19 vaccines approved for use in the U.S. include Pfizer (PFE) and BioNTech (BNTX), Moderna (MRNA), and Johnson & Johnson (JNJ). Reference Link

ShowHide Related Items >><<
PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

PFE Pfizer
$55.66 /

-0.98 (-1.73%)

01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

12/22/21 Kempen
BioNTech upgraded to Buy from Neutral at Kempen
12/21/21 H.C. Wainwright
BioNTech price target raised to $366 from $360 at H.C. Wainwright
12/16/21 Morgan Stanley
BioNTech initiated with an Equal Weight at Morgan Stanley
12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
MRNA Moderna
$211.34 /

-11.51 (-5.16%)

01/06/22 Argus
Moderna price target lowered to $350 from $420 at Argus
01/05/22 Piper Sandler
Piper keeps $348 target on Moderna after Epstein-Barr vaccine trial starts
12/20/21 Piper Sandler
Piper keeps Overweight rating, $348 price target on Moderna after omicron data
12/16/21 Piper Sandler
Arcturus data shows 'legit player' in COVID vaccines, says Piper Sandler
JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

PFE Pfizer
$55.66 /

-0.98 (-1.73%)

MRNA Moderna
$211.34 /

-11.51 (-5.16%)

JNJ Johnson & Johnson
$169.17 /

-0.64 (-0.38%)

BNTX BioNTech
$206.90 /

-14.28 (-6.46%)

Hot Stocks
Supreme Court blocks OSHA vaccine mandate for large businesses » 14:41
01/13/22
01/13
14:41
01/13/22
14:41
PFE

Pfizer

$55.71 /

-0.93 (-1.64%)

, BNTX

BioNTech

$206.66 /

-14.52 (-6.56%)

, MRNA

Moderna

$211.35 /

-11.5 (-5.16%)

, JNJ

Johnson & Johnson

$169.10 /

-0.71 (-0.42%)

The Supreme Court stated…

The Supreme Court stated in a ruling posted to its site: "The Secretary of Labor, acting through the Occupational Safety and Health Administration, recently enacted a vaccine mandate for much of the Nation's work force. The mandate, which employers must enforce, applies to roughly 84 million workers, covering virtually all employers with at least 100 employees. It requires that covered workers receive a COVID-19 vaccine, and it pre-empts contrary state laws. The only exception is for workers who obtain a medical test each week at their own expense and on their own time, and also wear a mask each workday... Applicants now seek emergency relief from this Court, arguing that OSHA's mandate exceeds its statutory authority and is otherwise unlawful. Agreeing that applicants are likely to prevail, we grant their applications and stay the rule... Although Congress has indisputably given OSHA the power to regulate occupational dangers, it has not given that agency the power to regulate public health more broadly. Requiring the vaccination of 84 million Americans, selected simply because they work for employers with more than 100 employees, certainly falls in the latter category... The applications for stays presented to JUSTICE KAVANAUGH and by him referred to the Court are granted." Makers of COVID-19 vaccines approved for use in the U.S. include Pfizer (PFE) and BioNTech (BNTX), Moderna (MRNA), and Johnson & Johnson (JNJ). Reference Link

ShowHide Related Items >><<
PFE Pfizer
$55.71 /

-0.93 (-1.64%)

MRNA Moderna
$211.35 /

-11.5 (-5.16%)

JNJ Johnson & Johnson
$169.10 /

-0.71 (-0.42%)

BNTX BioNTech
$206.66 /

-14.52 (-6.56%)

PFE Pfizer
$55.71 /

-0.93 (-1.64%)

01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
BNTX BioNTech
$206.66 /

-14.52 (-6.56%)

12/22/21 Kempen
BioNTech upgraded to Buy from Neutral at Kempen
12/21/21 H.C. Wainwright
BioNTech price target raised to $366 from $360 at H.C. Wainwright
12/16/21 Morgan Stanley
BioNTech initiated with an Equal Weight at Morgan Stanley
12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
MRNA Moderna
$211.35 /

-11.5 (-5.16%)

01/06/22 Argus
Moderna price target lowered to $350 from $420 at Argus
01/05/22 Piper Sandler
Piper keeps $348 target on Moderna after Epstein-Barr vaccine trial starts
12/20/21 Piper Sandler
Piper keeps Overweight rating, $348 price target on Moderna after omicron data
12/16/21 Piper Sandler
Arcturus data shows 'legit player' in COVID vaccines, says Piper Sandler
JNJ Johnson & Johnson
$169.10 /

-0.71 (-0.42%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
PFE Pfizer
$55.71 /

-0.93 (-1.64%)

MRNA Moderna
$211.35 /

-11.5 (-5.16%)

JNJ Johnson & Johnson
$169.10 /

-0.71 (-0.42%)

BNTX BioNTech
$206.66 /

-14.52 (-6.56%)

PFE Pfizer
$55.71 /

-0.93 (-1.64%)

MRNA Moderna
$211.35 /

-11.5 (-5.16%)

JNJ Johnson & Johnson
$169.10 /

-0.71 (-0.42%)

BNTX BioNTech
$206.66 /

-14.52 (-6.56%)

PFE Pfizer
$55.71 /

-0.93 (-1.64%)

MRNA Moderna
$211.35 /

-11.5 (-5.16%)

JNJ Johnson & Johnson
$169.10 /

-0.71 (-0.42%)

BNTX BioNTech
$206.66 /

-14.52 (-6.56%)

PFE Pfizer
$55.71 /

-0.93 (-1.64%)

MRNA Moderna
$211.35 /

-11.5 (-5.16%)

JNJ Johnson & Johnson
$169.10 /

-0.71 (-0.42%)

BNTX BioNTech
$206.66 /

-14.52 (-6.56%)

Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/13/22
01/13
04:55
01/13/22
04:55
ABBV

AbbVie

$135.88 /

+0.24 (+0.18%)

, ALLO

Allogene Therapeutics

$12.32 /

-0.545 (-4.24%)

, BAX

Baxter

$86.43 /

+0.08 (+0.09%)

, BHG

Bright Health

$3.13 /

-0.085 (-2.65%)

, TWST

Twist Bioscience

$62.99 /

-4.11 (-6.13%)

, TXG

10x Genomics

$118.89 /

-2.99 (-2.45%)

, TDOC

Teladoc

$81.83 /

-4.47 (-5.18%)

, SRRK

Scholar Rock

$21.55 /

-0.53 (-2.40%)

, SLDB

Solid Biosciences

$1.49 /

-0.06 (-3.87%)

, RLAY

Relay Therapeutics

$26.12 /

-1.57 (-5.67%)

, QSI

Quantum-Si

$6.01 /

-0.28 (-4.45%)

, QDEL

Quidel

$124.62 /

-2.9099 (-2.28%)

, DAWN

Day One Biopharmaceuticals

$15.39 /

+0.28 (+1.85%)

, CERN

Cerner

$92.21 /

-0.04 (-0.04%)

, BRKR

Bruker

$73.60 /

+0.55 (+0.75%)

, BNTX

BioNTech

$221.16 /

+5.13 (+2.37%)

, BEAM

Beam Therapeutics

$70.23 /

-5.49 (-7.25%)

, MOR

MorphoSys

$8.99 /

-0.205 (-2.23%)

, MOLN

Molecular Partners

$27.00 /

+1.34 (+5.22%)

, MODV

ModivCare

$133.23 /

-1.36 (-1.01%)

, MYGN

Myriad Genetics

$26.17 /

-0.37 (-1.39%)

, CI

Cigna

$238.85 /

-1.1 (-0.46%)

, CRNX

Crinetics

$24.65 /

-0.85 (-3.33%)

, DNA

Ginkgo Bioworks

$6.26 /

-0.575 (-8.42%)

, ENDP

Endo

$3.54 /

-0.165 (-4.45%)

, JNJ

Johnson & Johnson

$169.83 /

-1.43 (-0.83%)

, GILD

Gilead

$72.24 /

-0.12 (-0.17%)

, HCAT

Health Catalyst

$33.50 /

-1.1 (-3.18%)

, HZNP

Horizon Therapeutics

$93.55 /

-2.38 (-2.48%)

, IART

Integra LifeSciences

$67.56 /

+0.36 (+0.54%)

, JAZZ

Jazz Pharmaceuticals

$144.87 /

-4.94 (-3.30%)

, IVA

Inventiva

$12.45 /

+ (+0.00%)

, ITOS

iTeos Therapeutics

$40.89 /

-0.64 (-1.54%)

, ITCI

Intra-Cellular

$39.77 /

-0.59 (-1.46%)

, MRNS

Marinus Pharmaceuticals

$10.85 /

-0.23 (-2.08%)

, NOVT

Novanta

$163.39 /

+0.07 (+0.04%)

, OMIC

Singular Genomics

$8.19 /

-0.35 (-4.10%)

, PACB

Pacific Biosciences

$14.46 /

-0.225 (-1.53%)

, RARE

Ultragenyx

$71.15 /

-1.64 (-2.25%)

, RAIN

Rain Therapeutics

$12.05 /

-0.83 (-6.44%)

, AMRS

Amyris

$5.28 /

+0.54 (+11.39%)

, ALKS

Alkermes

$24.24 /

-0.76 (-3.04%)

, NPCE

NeuroPace

$11.55 /

+0.8 (+7.44%)

, NVRO

Nevro

$90.88 /

-0.27 (-0.30%)

, SEER

Seer

$20.48 /

-0.03 (-0.15%)

, STTK

Shattuck Labs

$7.34 /

+0.06 (+0.82%)

, TLIS

Talis Biomedical

$3.24 /

-0.07 (-2.11%)

40th Annual Healthcare…

40th Annual Healthcare Virtual Conference to be held on January 10-13.Webcast Link

ShowHide Related Items >><<
TXG 10x Genomics
$118.89 /

-2.99 (-2.45%)

TWST Twist Bioscience
$62.99 /

-4.11 (-6.13%)

TLIS Talis Biomedical
$3.24 /

-0.07 (-2.11%)

TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

STTK Shattuck Labs
$7.34 /

+0.06 (+0.82%)

SRRK Scholar Rock
$21.55 /

-0.53 (-2.40%)

SLDB Solid Biosciences
$1.49 /

-0.06 (-3.87%)

SEER Seer
$20.48 /

-0.03 (-0.15%)

RLAY Relay Therapeutics
$26.12 /

-1.57 (-5.67%)

RARE Ultragenyx
$71.15 /

-1.64 (-2.25%)

RAIN Rain Therapeutics
$12.05 /

-0.83 (-6.44%)

QSI Quantum-Si
$6.01 /

-0.28 (-4.45%)

QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

OMIC Singular Genomics
$8.19 /

-0.35 (-4.10%)

NVRO Nevro
$90.88 /

-0.27 (-0.30%)

NPCE NeuroPace
$11.55 /

+0.8 (+7.44%)

NOVT Novanta
$163.39 /

+0.07 (+0.04%)

MYGN Myriad Genetics
$26.17 /

-0.37 (-1.39%)

MRNS Marinus Pharmaceuticals
$10.85 /

-0.23 (-2.08%)

MOR MorphoSys
$8.99 /

-0.205 (-2.23%)

MOLN Molecular Partners
$27.00 /

+1.34 (+5.22%)

MODV ModivCare
$133.23 /

-1.36 (-1.01%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

JAZZ Jazz Pharmaceuticals
$144.87 /

-4.94 (-3.30%)

IVA Inventiva
$12.45 /

+ (+0.00%)

ITOS iTeos Therapeutics
$40.89 /

-0.64 (-1.54%)

ITCI Intra-Cellular
$39.77 /

-0.59 (-1.46%)

IART Integra LifeSciences
$67.56 /

+0.36 (+0.54%)

HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

DAWN Day One Biopharmaceuticals
$15.39 /

+0.28 (+1.85%)

CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BRKR Bruker
$73.60 /

+0.55 (+0.75%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BHG Bright Health
$3.13 /

-0.085 (-2.65%)

BEAM Beam Therapeutics
$70.23 /

-5.49 (-7.25%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

ALKS Alkermes
$24.24 /

-0.76 (-3.04%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

01/12/22 BMO Capital
AbbVie price target raised to $153 from $134 at BMO Capital
01/11/22 Piper Sandler
AbbVie long range estimates need to come up, says Piper Sandler
01/05/22 Mizuho
Mizuho keeps AbbVie as top 2022 large cap pick, ups target
01/03/22 Piper Sandler
AbbVie price target raised to $160 from $129 at Piper Sandler
ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

01/10/22 Stifel
Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
01/06/22 Wells Fargo
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
01/03/22 Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
BAX Baxter
$86.43 /

+0.08 (+0.09%)

01/07/22 Morgan Stanley
Baxter upgraded to Overweight at Morgan Stanley after 'transformative' deal
01/07/22 Citi
Baxter resumed with a Buy at Citi
01/07/22 Morgan Stanley
Baxter upgraded to Overweight from Equal Weight at Morgan Stanley
01/04/22 Raymond James
Baxter price target raised to $99 from $93 at Raymond James
BHG Bright Health
$3.13 /

-0.085 (-2.65%)

01/10/22 Citi
Bright Health assumed with a Neutral at Citi
01/07/22 Barclays
Bright Health price target lowered to $5.50 from $9 at Barclays
12/17/21 Morgan Stanley
Bright Health downgraded to Underweight at Morgan Stanley
12/16/21 Morgan Stanley
Bright Health downgraded to Underweight from Equal Weight at Morgan Stanley
TWST Twist Bioscience
$62.99 /

-4.11 (-6.13%)

11/26/21 Benchmark
Recent deals highlight value in ImmunoPrecise shares, says Benchmark
11/23/21 Baird
Twist Bioscience price target lowered to $113 from $130 at Baird
10/14/21 Cowen
Twist Bioscience coverage transferred at Cowen
08/09/21 Baird
Twist Bioscience price target lowered to $130 from $140 at Baird
TXG 10x Genomics
$118.89 /

-2.99 (-2.45%)

10/14/21 Cowen
10x Genomics coverage transferred at Cowen
09/14/21
Fly Intel: Top five analyst downgrades
09/14/21 BofA
10x Genomics downgraded on 'incrementally more negative' tone at BofA
09/14/21 BofA
10x Genomics downgraded to Neutral from Buy at BofA
TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

01/11/22 Piper Sandler
Teladoc price target lowered to $118 from $183 at Piper Sandler
12/02/21 Baird
Teladoc elevated to bullish Fresh Pick at Baird
12/01/21 Jefferies
Teladoc assumed with a Hold at Jefferies
11/23/21 Canaccord
Teladoc price target lowered to $160 from $188 at Canaccord
SRRK Scholar Rock
$21.55 /

-0.53 (-2.40%)

12/22/21 Jefferies
Scholar Rock downgraded to Hold on lack of catalysts at Jefferies
12/22/21 Jefferies
Scholar Rock downgraded to Hold from Buy at Jefferies
11/18/21 Piper Sandler
Scholar Rock initiated with an Overweight at Piper Sandler
06/11/21 BMO Capital
Scholar Rock coverage transferred at BMO Capital
SLDB Solid Biosciences
$1.49 /

-0.06 (-3.87%)

09/24/21 Chardan
Solid Biosciences price target lowered to $17 from $20 at Chardan
09/23/21 Piper Sandler
Piper Sandler 'cautiously optimistic' on Solid Biosciences after update
07/12/21 Piper Sandler
Solid Biosciences initiated with a Neutral at Piper Sandler
07/09/21 Chardan
Solid Biosciences coverage transferred at Chardan
RLAY Relay Therapeutics
$26.12 /

-1.57 (-5.67%)

01/03/22 Guggenheim
Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
11/08/21 Jefferies
Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
08/17/21 H.C. Wainwright
Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
07/21/21 BofA
BofA starts possible 'breakout star' Relay Therapeutics at Buy
QSI Quantum-Si
$6.01 /

-0.28 (-4.45%)

10/20/21 Canaccord
Quantum-Si initiated with a Buy at Canaccord
QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

12/27/21 Raymond James
Quidel acquisition brings 'lower ceiling on growth,' says Raymond James
12/27/21 H.C. Wainwright
Ortho Clinical downgraded to Neutral from Buy at H.C. Wainwright
12/23/21 Evercore ISI
Evercore downgrades Ortho Clinical to In Line, doesn't see risk to deal closing
12/23/21
Fly Intel: Top five analyst downgrades
DAWN Day One Biopharmaceuticals
$15.39 /

+0.28 (+1.85%)

06/21/21 Cowen
Cowen starts Day One with Outperform on glioma potential
06/21/21 JPMorgan
Day One Biopharmaceuticals initiated with an Overweight at JPMorgan
06/21/21 Wedbush
Day One Biopharmaceuticals initiated with an Outperform at Wedbush
06/21/21 Wedbush
Day One Biopharmaceuticals initiated with an Outperform at Wedbush
CERN Cerner
$92.21 /

-0.04 (-0.04%)

01/06/22 Monness Crespi
Oracle selloff creates 'attractive buying opportunity,' says Monness Crespi
12/21/21 KeyBanc
Cerner downgraded to Sector Weight from Overweight at KeyBanc
12/21/21 Deutsche Bank
Oracle investors will come to appreciate Cerner deal, says Deutsche Bank
12/21/21 KeyBanc
KeyBanc downgrades Oracle, calls Cerner deal non-strategic
BRKR Bruker
$73.60 /

+0.55 (+0.75%)

10/14/21 Cowen
Bruker coverage transferred at Cowen
08/03/21 Wells Fargo
Bruker price target raised to $85 from $70 at Wells Fargo
08/03/21 Citi
Bruker price target raised to $85 from $75 at Citi
06/15/21 Cleveland Research
Bruker upgraded to Buy from Neutral at Cleveland Research
BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

12/22/21 Kempen
BioNTech upgraded to Buy from Neutral at Kempen
12/21/21 H.C. Wainwright
BioNTech price target raised to $366 from $360 at H.C. Wainwright
12/16/21 Morgan Stanley
BioNTech initiated with an Equal Weight at Morgan Stanley
12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
BEAM Beam Therapeutics
$70.23 /

-5.49 (-7.25%)

01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
MOR MorphoSys
$8.99 /

-0.205 (-2.23%)

01/04/22 JPMorgan
MorphoSys price target lowered to EUR 40 from EUR 54 at JPMorgan
11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
MOLN Molecular Partners
$27.00 /

+1.34 (+5.22%)

08/10/21 Credit Suisse
Molecular Partners price target lowered to CHF 18.50 at Credit Suisse
07/12/21 Cowen
Molecular Partners initiated with an Outperform at Cowen
07/12/21 RBC Capital
Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital
07/12/21 SVB Leerink
Molecular Partners assumed with an Outperform at SVB Leerink
MODV ModivCare
$133.23 /

-1.36 (-1.01%)

12/17/21 Deutsche Bank
ModivCare initiated with a Buy at Deutsche Bank
08/04/21 Barrington
ModivCare price target raised to $186 from $170 at Barrington
05/10/21 Barrington
ModivCare price target raised to $170 from $162 at Barrington
MYGN Myriad Genetics
$26.17 /

-0.37 (-1.39%)

10/14/21 Cowen
Myriad Genetics coverage transferred at Cowen
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
CI Cigna
$238.85 /

-1.1 (-0.46%)

01/11/22 Bernstein
Cigna price target raised to $258 from $234 at Bernstein
01/06/22 Wells Fargo
Wells Fargo upgrades Cigna to Overweight, raises price target to $278
01/06/22 Wells Fargo
Cigna upgraded to Overweight from Equal Weight at Wells Fargo
01/05/22 Truist
Cigna price target raised to $275 from $270 at Truist
CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

11/30/21 JMP Securities
Crinetics initiated with an Outperform at JMP Securities
11/23/21 Evercore ISI
Evercore starts 'rare endo treasure trove' Crinetics at Outperform
11/23/21 Evercore ISI
Crinetics initiated with an Outperform at Evercore ISI
06/18/21 JPMorgan
Crinetics upgraded to Overweight ahead of data at JPMorgan
DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ENDP Endo
$3.54 /

-0.165 (-4.45%)

12/16/21 Barclays
Endo price target lowered to $5 from $7 at Barclays
11/05/21 Stifel
Endo's performance tempering 'noise' around litigation, says Stifel
08/31/21 Piper Sandler
Endo downgraded to Neutral at Piper Sandler following Vasostrict ruling loss
08/31/21 Piper Sandler
Endo downgraded to Neutral from Overweight at Piper Sandler
JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
GILD Gilead
$72.24 /

-0.12 (-0.17%)

01/06/22 Morgan Stanley
Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
12/22/21 Piper Sandler
Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
12/22/21 Morgan Stanley
Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
12/15/21 Jefferies
Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
HCAT Health Catalyst
$33.50 /

-1.1 (-3.18%)

12/01/21 Jefferies
Health Catalyst initiated with a Hold at Jefferies
10/14/21 BTIG
Health Catalyst initiated with a Buy at BTIG
08/10/21 RBC Capital
Health Catalyst price target raised to $66 from $60 at RBC Capital
08/06/21 Canaccord
Health Catalyst price target raised to $64 from $60 at Canaccord
HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

12/08/21
Fly Intel: Top five analyst initiations
12/08/21 Wells Fargo
Horizon Therapeutics initiated with an Overweight at Wells Fargo
11/18/21 Goldman Sachs
Horizon Therapeutics upgraded to Buy from Neutral at Goldman Sachs
10/12/21 Evercore ISI
Evercore starts Viridian at Outperform on thyroid eye disease opportunity
IART Integra LifeSciences
$67.56 /

+0.36 (+0.54%)

12/17/21 JPMorgan
Integra LifeSciences upgraded to Neutral on recent changes at JPMorgan
12/17/21 JPMorgan
Integra LifeSciences upgraded to Neutral from Underweight at JPMorgan
12/15/21 Citi
Integra LifeSciences price target lowered to $70 from $78 at Citi
10/28/21 Piper Sandler
Integra LifeSciences new CEO 'seems solid,' says Piper Sandler
JAZZ Jazz Pharmaceuticals
$144.87 /

-4.94 (-3.30%)

12/22/21 JPMorgan
Jazz Pharmaceuticals shares offer attractive entry point, says JPMorgan
12/20/21 SVB Leerink
Jazz Pharmaceuticals price target lowered to $200 from $230 at SVB Leerink
12/17/21 Needham
Jazz Pharmaceuticals price target lowered to $215 from $220 at Needham
11/18/21 Goldman Sachs
Jazz Pharmaceuticals reinstated with a Buy at Goldman Sachs
IVA Inventiva
$12.45 /

+ (+0.00%)

11/22/21 H.C. Wainwright
Inventiva price target raised to $42 from $40 at H.C. Wainwright
09/22/21 H.C. Wainwright
Inventiva price target raised to $40 from $38 at H.C. Wainwright
05/04/21 Roth Capital
Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
03/08/21
Fly Intel: Top five analyst downgrades
ITOS iTeos Therapeutics
$40.89 /

-0.64 (-1.54%)

12/16/21 Wedbush
iTeos Therapeutics added to 'Best Ideas List' at Wedbush
12/13/21 H.C. Wainwright
iTeos Therapeutics price target raised to $54 from $37 at H.C. Wainwright
11/11/21 Piper Sandler
iTeos Therapeutics price target lowered to $42 from $50 at Piper Sandler
06/14/21 Piper Sandler
iTeos deal 'addresses a number of needs all at once, says Piper Sandler
ITCI Intra-Cellular
$39.77 /

-0.59 (-1.46%)

12/21/21 RBC Capital
Intra-Cellular price target raised to $55 from $50 at RBC Capital
12/21/21 Jefferies
Intra-Cellular price target raised to $85 from $70 at Jefferies
12/20/21 Canaccord
Intra-Cellular price target raised to $88 from $81 at Canaccord
12/20/21 SVB Leerink
Intra-Cellular price target raised to $50 from $45 at SVB Leerink
MRNS Marinus Pharmaceuticals
$10.85 /

-0.23 (-2.08%)

08/18/21 Truist
Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
03/10/21 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
NOVT Novanta
$163.39 /

+0.07 (+0.04%)

OMIC Singular Genomics
$8.19 /

-0.35 (-4.10%)

01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/06/22 UBS
Singular Genomics price target lowered to $25 from $32 at UBS
10/14/21 Cowen
Singular Genomics coverage transferred at Cowen
PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

01/11/22 Piper Sandler
Pacific Biosciences has new competitor in Illumina, says Piper Sandler
01/05/22 Piper Sandler
Pacific Biosciences assumed with a Neutral at Piper Sandler
10/14/21 Cowen
Pacific Biosciences coverage transferred at Cowen
09/27/21 Canaccord
Pacific Biosciences initiated with a Buy at Canaccord
RARE Ultragenyx
$71.15 /

-1.64 (-2.25%)

01/05/22 Stifel
Stifel bullish on Ultragenyx, sees GTX-102 update as tailwind toward mid-22 data
11/03/21 Citi
Ultragenyx trading at 'significant discount to fair value,' says Citi
09/30/21 H.C. Wainwright
Ultragenyx initiated with a Buy at H.C. Wainwright
09/27/21 Piper Sandler
Piper 'incrementally positive' on Ultragenyx after clinical hold lift
RAIN Rain Therapeutics
$12.05 /

-0.83 (-6.44%)

01/03/22 Guggenheim
Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
11/10/21 Piper Sandler
Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
09/14/21 Goldman Sachs
Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
AMRS Amyris
$5.28 /

+0.54 (+11.39%)

11/09/21 Roth Capital
Amyris price target lowered to $15 from $22 at Roth Capital
10/14/21 Cowen
Amyris coverage transferred at Cowen
08/06/21 H.C. Wainwright
Amyris price target lowered to $30 from $35 at H.C. Wainwright
07/06/21 HSBC
Amyris is at 'tipping point on growth,' says HSBC
ALKS Alkermes
$24.24 /

-0.76 (-3.04%)

12/01/21 Citi
Alkermes initiated with a Neutral at Citi
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
10/28/21 Mizuho
Alkermes shares have 25% upside after selloff, says Mizuho
10/28/21 H.C. Wainwright
Alkermes price target raised to $30 from $25 at H.C. Wainwright
NPCE NeuroPace
$11.55 /

+0.8 (+7.44%)

01/07/22 Morgan Stanley
NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
01/07/22 Morgan Stanley
NeuroPace downgraded to Underweight from Equal Weight at Morgan Stanley
12/17/21 Baird
NeuroPace price target lowered to $20 from $23 at Baird
11/11/21 Morgan Stanley
Morgan Stanley downgrades NeuroPace on more uncertain recovery pace
NVRO Nevro
$90.88 /

-0.27 (-0.30%)

01/12/22 Canaccord
Nevro price target lowered to $97 from $118 at Canaccord
01/07/22 Morgan Stanley
Nevro downgraded to Equal Weight at Morgan Stanley on COVID and competition
01/07/22 Morgan Stanley
Nevro downgraded to Equal Weight from Overweight at Morgan Stanley
01/07/22 Piper Sandler
Nevro price target raised to $92 from $90 at Piper Sandler
SEER Seer
$20.48 /

-0.03 (-0.15%)

10/14/21 Cowen
Seer coverage transferred at Cowen
08/13/21 Morgan Stanley
Seer price target lowered to $50 from $55 at Morgan Stanley
STTK Shattuck Labs
$7.34 /

+0.06 (+0.82%)

04/14/21 Berenberg
Shattuck Labs initiated with a Buy at Berenberg
01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
TLIS Talis Biomedical
$3.24 /

-0.07 (-2.11%)

01/07/22 BofA
Talis Biomedical downgraded to Underperform from Neutral at BofA
09/27/21 JPMorgan
Talis Biomedical downgraded to Underweight from Neutral at JPMorgan
08/31/21 BTIG
Talis Biomedical downgraded to Neutral at BTIG following CEO departure
08/31/21 BTIG
Talis Biomedical downgraded to Neutral from Buy at BTIG
TXG 10x Genomics
$118.89 /

-2.99 (-2.45%)

TWST Twist Bioscience
$62.99 /

-4.11 (-6.13%)

TLIS Talis Biomedical
$3.24 /

-0.07 (-2.11%)

TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

STTK Shattuck Labs
$7.34 /

+0.06 (+0.82%)

SRRK Scholar Rock
$21.55 /

-0.53 (-2.40%)

SLDB Solid Biosciences
$1.49 /

-0.06 (-3.87%)

SEER Seer
$20.48 /

-0.03 (-0.15%)

RLAY Relay Therapeutics
$26.12 /

-1.57 (-5.67%)

RARE Ultragenyx
$71.15 /

-1.64 (-2.25%)

RAIN Rain Therapeutics
$12.05 /

-0.83 (-6.44%)

QSI Quantum-Si
$6.01 /

-0.28 (-4.45%)

QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

OMIC Singular Genomics
$8.19 /

-0.35 (-4.10%)

NVRO Nevro
$90.88 /

-0.27 (-0.30%)

NPCE NeuroPace
$11.55 /

+0.8 (+7.44%)

NOVT Novanta
$163.39 /

+0.07 (+0.04%)

MYGN Myriad Genetics
$26.17 /

-0.37 (-1.39%)

MRNS Marinus Pharmaceuticals
$10.85 /

-0.23 (-2.08%)

MOR MorphoSys
$8.99 /

-0.205 (-2.23%)

MODV ModivCare
$133.23 /

-1.36 (-1.01%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

JAZZ Jazz Pharmaceuticals
$144.87 /

-4.94 (-3.30%)

ITOS iTeos Therapeutics
$40.89 /

-0.64 (-1.54%)

ITCI Intra-Cellular
$39.77 /

-0.59 (-1.46%)

IART Integra LifeSciences
$67.56 /

+0.36 (+0.54%)

HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

HCAT Health Catalyst
$33.50 /

-1.1 (-3.18%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

DAWN Day One Biopharmaceuticals
$15.39 /

+0.28 (+1.85%)

CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BRKR Bruker
$73.60 /

+0.55 (+0.75%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BHG Bright Health
$3.13 /

-0.085 (-2.65%)

BEAM Beam Therapeutics
$70.23 /

-5.49 (-7.25%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

ALKS Alkermes
$24.24 /

-0.76 (-3.04%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

  • 05
    Jan
  • 21
    Oct
  • 13
    Oct
  • 11
    Aug
  • 24
    Jun
  • 16
    Jun
  • 27
    May
  • 27
    May
  • 23
    Apr
  • 22
    Apr
  • 09
    Apr
  • 08
    Apr
  • 19
    Mar
  • 12
    Feb
  • 28
    Jan
SEER Seer
$20.48 /

-0.03 (-0.15%)

QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

NPCE NeuroPace
$11.55 /

+0.8 (+7.44%)

MYGN Myriad Genetics
$26.17 /

-0.37 (-1.39%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

TWST Twist Bioscience
$62.99 /

-4.11 (-6.13%)

TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

SEER Seer
$20.48 /

-0.03 (-0.15%)

RLAY Relay Therapeutics
$26.12 /

-1.57 (-5.67%)

RARE Ultragenyx
$71.15 /

-1.64 (-2.25%)

QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

NVRO Nevro
$90.88 /

-0.27 (-0.30%)

MOR MorphoSys
$8.99 /

-0.205 (-2.23%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

JAZZ Jazz Pharmaceuticals
$144.87 /

-4.94 (-3.30%)

ITCI Intra-Cellular
$39.77 /

-0.59 (-1.46%)

IART Integra LifeSciences
$67.56 /

+0.36 (+0.54%)

HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

HCAT Health Catalyst
$33.50 /

-1.1 (-3.18%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BRKR Bruker
$73.60 /

+0.55 (+0.75%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BHG Bright Health
$3.13 /

-0.085 (-2.65%)

BEAM Beam Therapeutics
$70.23 /

-5.49 (-7.25%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

ALKS Alkermes
$24.24 /

-0.76 (-3.04%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

STTK Shattuck Labs
$7.34 /

+0.06 (+0.82%)

PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

ITOS iTeos Therapeutics
$40.89 /

-0.64 (-1.54%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BHG Bright Health
$3.13 /

-0.085 (-2.65%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.